Bactericidal Effect of Cecropin A Fused Endolysin on Drug-Resistant Gram-Negative Pathogens
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The rapid spread of superbugs leads to the escalation of infectious diseases, which threatens public health. Endolysins derived from bacteriophages are spotlighted as promising alternative antibiotics against multi-drug resistant bacteria. In this study, we isolated and characterized the novel Salmonella typhimurium phage PBST08. Bioinformatics analysis of the PBST08 genome revealed putative endolysin ST01 with a lysozyme-like domain. Since the lytic activity of the purified ST01 was minor, probably owing to the outer membrane, which blocks accessibility to peptidoglycan, antimicrobial peptide cecropin A (CecA) was fused to the N-terminus of ST01 to disrupt the outer membrane. The resulting CecA::ST01 has been shown to have increased bactericidal activity against gram-negative pathogens including Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Escherichia coli, and Enterobacter cloacae and the most affected target was A. baumannii. In the presence of 0.25 μM CecA::ST01, A. baumannii ATCC 17978 strain was completely killed and CCARM 12026 strain was wiped out by 0.5 μM CecA::ST01, which is a clinical isolate of A. baumannii and resistant to multiple drugs including carbapenem. Moreover, the larvae of Galleria mellonella could be rescued up to 58% or 49% by the administration of CecA::ST01 upon infection by A. baumannii 17978 or CCARM 12026 strain. Finally, the antibacterial activity of CecA::ST01 was verified using 31 strains of five gram-negative pathogens by evaluation of minimal inhibitory concentration. Thus, the results indicate that a fusion of antimicrobial peptide to endolysin can enhance antibacterial activity and the spectrum of endolysin where multi-drug resistant gramnegative pathogens can be efficiently controlled.
Abstract
The rapid spread of superbugs leads to the escalation of infectious diseases, which threatens public health. Endolysins derived from bacteriophages are spotlighted as promising alternative antibiotics against multi-drug resistant bacteria. In this study, we isolated and characterized the novel Salmonella typhimurium phage PBST08. Bioinformatics analysis of the PBST08 genome revealed putative endolysin ST01 with a lysozyme-like domain. Since the lytic activity of the purified ST01 was minor, probably owing to the outer membrane, which blocks accessibility to peptidoglycan, antimicrobial peptide cecropin A (CecA) was fused to the N-terminus of ST01 to disrupt the outer membrane. The resulting CecA::ST01 has been shown to have increased bactericidal activity against gram-negative pathogens including Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Escherichia coli, and Enterobacter cloacae and the most affected target was A. baumannii. In the presence of 0.25 μM CecA::ST01, A. baumannii ATCC 17978 strain was completely killed and CCARM 12026 strain was wiped out by 0.5 μM CecA::ST01, which is a clinical isolate of A. baumannii and resistant to multiple drugs including carbapenem. Moreover, the larvae of Galleria mellonella could be rescued up to 58% or 49% by the administration of CecA::ST01 upon infection by A. baumannii 17978 or CCARM 12026 strain. Finally, the antibacterial activity of CecA::ST01 was verified using 31 strains of five gram-negative pathogens by evaluation of minimal inhibitory concentration. Thus, the results indicate that a fusion of antimicrobial peptide to endolysin can enhance antibacterial activity and the spectrum of endolysin where multi-drug resistant gramnegative pathogens can be efficiently controlled.
참고문헌 (32)
- Ligon BL, "Penicillin : its discovery and early development", Semin. Pediatr. Infect. Dis, 15, pp.52~57 (2004)
- Lewis K, "Antibiotics : recover the lost art of drug discovery", Nature, 485, pp.439~440 (2012)
- Martínez JL, "Emergence and spread of antibiotic resistance : setting a parameter space", Ups. J. Med. Sci, 119, pp.68~77 (2014)
- Jim O’Neill, "Nature Reviews Drug Discovery", Nature, 15, pp.526~ (2016)
- Magiorakos A-P, "Multidrug-resistant, extensively drugresistant and pandrug-resistant bacteria : an international expert proposal for interim standard definitions for acquired resistance", Clin. Microbiol. Infect, 18, pp.268~281 (2012)
- Bassetti M, "Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug-resistant", extensively drug-resistant, Curr. Opin. Crit. Care, pp.2018, 24[DOI]
- Chegini Z, "Bacteriophage therapy for inhibition of multi drugresistant uropathogenic bacteria : a narrative review", Ann. Clin. Microbiol. Antimicrob, 20, pp.30~ (2021)
- Bhargava K, "Phage therapeutics : from promises to practices and prospectives", Appl. Microbiol. Biotechnol, 105, pp.9047~9067 (2021)
- Mousavi SM, "Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant Gram-negative bacteria", Curr. Microbiol, 78, pp.4023~4036 (2021)
- Labrie SJ, "Bacteriophage resistance mechanisms", Nat. Rev. Microbiol, 8, pp.317~327 (2010)
- Meile S, "Engineering therapeutic phages for enhanced antibacterial efficacy", Curr. Opin. Virol, 52, pp.182~191 (2021)
- Samson JE, "Revenge of the phages : defeating bacterial defences", Nat. Rev. Microbiol, 11, pp.675~687 (2013)
- Young I, "Phages will out : strategies of host cell lysis", Trends Microbiol, 8, pp.120~128 (2000)
- Nelson D, "Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme", Proc. Natl. Acad. Sci. USA, 98, pp.4107~4112 (2001)
- Jado I, "Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model", J. Antimicrob. Chemother, 52, pp.967~973 (2003)
- Traczewski MM, "Determination of MIC quality control parameters for exebacase, a novel lysin with antistaphylococcal activity", J. Clin. Microbiol, 59, pp.e0311720~ (2021)
- Nelson DC, "Endolysins as antimicrobials", Adv. Virus Res, 83, pp.299~365 (2012)
- Yves Briers, "Engineered Endolysin-Based “Artilysins” To Combat Multidrug-Resistant Gram-Negative Pathogens", mBio, 5(4) (2014), American Society for Microbiology[DOI]
- Briers Y, "Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa", Antimicrob. Agents Chemother, 58, pp.3774~3784 (2014)
- Saeed SI, "Antimicrobial peptides : bringing solution to the rising threats of antimicrobial resistance in livestock", Front. Vet. Sci, 9, pp.851052~ (2022)
- Moore AJ, "Antimicrobial activity of cecropins", J. Antimicrob. Chemother, 37, pp.1077~1089 (1996)
- Abdelkader K, "Engineering a lysin with intrinsic antibacterial activity(LysMK34)by cecropin A fusion enhances its antibacterial properties against Acinetobacter baumannii", Appl. Environ. Microbiol, 88, pp.e0151521~ (2022)
- Hong H-W, "Combination effect of engineered endolysin EC340 with antibiotics", Front. Microbiol, 13, pp.821936~ (2022)
- Hockett KL, "Use of the soft-agar overlay technique to screen for bacterially produced inhibitory compounds", J. Vis. Exp, 14, pp.55064~ (2017)
- Kim MS, "Phage-encoded colanic acid-degrading enzyme permits lytic phage infection of a capsule-forming resistant mutant Escherichia coli strain", Appl. Environ. Microbiol, 81, pp.900~909 (2015)
- Gouet P, "ESPript : analysis of multiple sequence alignments in PostScript", Bioinformatics, 15, pp.305~308 (1999)
- Sievers F, "Clustal Omega for making accurate alignments of many protein sequences", Protein Sci, 27, pp.135~145 (2018)
- Quevillon E, "InterProScan : protein domains identifier", Nucleic Acids Res, 33, pp.116~120 (2005)
- Blasco L, "In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens", Sci. Rep, 10, pp.7163~ (2020)
- Murray E, "The advantages and challenges of using endolysins in a clinical setting", Viruses, 13, pp.680~ (2021)
- Gerstmans H, "From endolysins to Artilysin®s : novel enzyme-based approaches to kill drug-resistant bacteria", Biochem. Soc. Trans, 44, pp.123~128 (2016)
- Briers Y, "Breaking barriers : expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria", Future Microbiol, 10, pp.377~390 (2015)